9 Results for "

DIO rats

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "DIO rats" in MCE Product Catalog:

Cat. No.: HY-P10745
CAS No.: 2766385-23-1
Synonyms: ZP8396
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
loading...
    loading...
Cat. No.: HY-P10745A
Synonyms: ZP8396 acetate
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
loading...
    loading...
Cat. No.: HY-P10302A
Target:  

GLP Receptor

GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
loading...
    loading...
Cat. No.: HY-177297
CAS No.: 1067877-83-1
Synonyms: NVP-LCZ960
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-112488
CAS No.: 1239893-96-9
Research Areas:  

Metabolic Disease

EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .
loading...
    loading...
Cat. No.: HY-P11587
Research Areas:  

Metabolic Disease

BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .
loading...
    loading...
Cat. No.: HY-P11843
Research Areas:  

Metabolic Disease

TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC50 values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes .
loading...
    loading...
Cat. No.: HY-P11830
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-182014
CAS No.: 2408041-54-1
Target:  

LXR

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
loading...
    loading...